Soluble receptors for advanced glycation end products (sRAGE) as a predictor of restenosis following percutaneous coronary intervention

Clinical Cardiology

Volumn 33, Issue 11, 2010, Pages 678-685

  McNair, Erick D ^a   Wells, Calvin R ^a   Mabood Qureshi, A ^a   Basran, Rashpal ^a   Pearce, Colin ^a   Orvold, Jason ^a   Devilliers, Jacobus ^a   Prasad, Kailash ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; PROTEIN BLOOD LEVEL; RESTENOSIS; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; ANGIOPLASTY, BALLOON, CORONARY; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CORONARY STENOSIS; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RECEPTORS, IMMUNOLOGIC; SASKATCHEWAN; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 78649639285     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20815     Document Type: Article

References (39)

1. Bucala R, Cerami A,. Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv Pharmacol 1992; 23: 1-34.
2. Prasad K,. Soluble receptors for advanced glycation end products (sRAGE) and cardiovascular disease. Int J Angiol 2006; 15: 57-68.
3. Schmidt A, Yan SD, Yan SF, et al., The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 2000; 1498: 99-111.
4. Yonekura H, Yamamoto Y, Sakurai S, et al., Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003; 370: 1097-1109.
5. Hudson B, Harja E, Moser B, et al., Soluble levels of receptor for advanced glycation endproducts (sRAGE) and coronary artery disease: the next C-reactive protein? Arterioscler Thromb Vasc Biol 2005; 25: 879-882.
6. Hofmann MA, Drury S, Fu C, et al., RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999; 97: 889-901.
7. Reznikov LL, Waksman J, Azam T, et al., Effect of advanced glycation end products on endotoxin-induced TNF-alpha, IL-1beta and IL-8 in human peripheral blood mononuclear cells. Clin Nephrol 2004; 61: 324-336.
8. Baeuerle P, Henkel T,. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 1994; 12: 141-179.
9. Yan SD, Schmidt AM, Anderson GM, et al., Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994; 269: 9889-9897.
10. Geroldi D, Falcone C, Emanuele E,. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem 2006; 13: 1971-1978.
11. Libby P, Ridker PM, Maseri A,. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-1143.
12. Prasad K,. Reduction of serum cholesterol and hypercholesterolemic atherosclerosis in rabbits by secoisolariciresinol diglucoside isolated from flaxseed. Circulation 1999; 99: 1355-1362.
13. Schmidt A, Stern D,. Atherosclerosis and diabetes: the RAGE connection. Curr Atheroscler Rep 2000; 2: 430-436.
14. Schmidt A, Yan S, Wautier JL, et al., Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999; 84: 489-497.
15. Zhou Z, Wang K, Penn MS, et al., Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation 2003; 107: 2238-2243.
16. Sakaguchi T, Yan SF, Yan SD, et al., Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 2003; 111: 959-972.
17. Park L, Raman KG, Lee KJ, et al., Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998; 4: 1025-1031.
18. Titcolor Bucciarelli LG Titcolor, Titcolor Wendt T, Titcolor, Titcolor Qu W, Titcolor, et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002; 106: 2827-2835.
19. Kastrati A, Mehilli J, Dirschinger J, et al., Restenosis after coronary placement of various stent types. Am J Cardiol 2001; 87: 34-39.
20. Macaya C, Serruys PW, Ruygrok P, et al.,; Benestent Study Group. Continued benefit of coronary stenting versus balloon angioplasty: one-year clinical follow-up of Benestent trial. J Am Coll Cardiol 1996; 27: 255-261.
21. Stone GW, Ellis SG, Cox DA, et al.,; TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-231.
22. Lafont A, Guzman LA, Whitlow PL, et al., Restenosis after experimental angioplasty: intimal, medial, and adventitial changes associated with constrictive remodeling. Circ Res 1995; 76: 996-1002.
23. Serruys PW, de Jaegere P, Kiemeneij F, et al,; Benestent Study Group. A comparison of balloon expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994; 331: 489-495.
24. Kuntz RE, Baim DS,. Defining coronary restenosis: newer clinical and angiographic paradigms. Circulation 1993; 88: 1310-1323.
25. Glas AS, Lijmer JG, Prins MH, et al., The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 2003; 56: 1129-1135.
26. Cutlip DE, Chauhan MS, Baim DS, et al., Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol 2002; 40: 2082-2089.
27. Lemos PA, Saia F, Ligthart JM, et al., Coronary restenosis after sirolimus-eluting stent implantation: morphological description and mechanistic analysis from a consecutive series of cases. Circulation 2003; 108: 257-260.
28. Falcone C, Emanuele E, D'Angelo A, et al., Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 2005; 25: 1032-1037. (Pubitemid 40627851)
29. Théroux P, Armstrong PW, Mahaffey KW, et al., Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial. Eur Heart J 2005; 26: 1964-1970.
30. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez MJ, et al., Light/dark patterns of soluble vascular cell adhesion molecule-1 in relation to melatonin in patients with ST-segment elevation myocardial infarction. J Pineal Res 2008; 44: 65-69.
31. Schmidt AM, Hori O, Chen JX, et al., Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultures human endothelial cells and in mice: a potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995; 96: 1395-1403.
32. Sorescu D, Griendling KK,. Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure. Congest Heart Fail 2002; 8: 132-140.
33. Downey JM, Omar B, Ooiwa H, et al., Superoxide dismutase therapy for myocardial ischemia. Free Radic Res Commun 1991; 12-13: 703-720.
34. Pritchard KA Jr, Groszek L, Smalley DM, et al., Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ Res 1995; 77: 510-518.
35. Kumar A, Takada Y, Boriek AM, et al., Nuclear factor-kappaB: its role in health and disease. J Mol Med 2004; 82: 434-448.
36. Goodwin BL, Pendleton LC, Levy MM, et al., Tumor necrosis factor-alpha reduces argininosuccinate synthase expression and nitric oxide production in aortic endothelial cells. Am J Physiol Heart Circ Physiol 2007; 293: H1115-H1121.
37. Gao X, Belmadani S, Picchi A, et al., Tumor necrosis factor-alpha induces endothelial dysfunction in Lepr(db) mice. Circulation 2007; 115: 245-254.
38. Prasad K, Lee P,. Suppression of hypercholesterolemic atherosclerosis by pentoxifylline and its mechanism. Atherosclerosis 2007; 192: 313-322.
39. Cooke JP, Singer AH, Tsao P, et al., Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest 1992; 90: 1168-1172.